CDMOs & CROs
Autumn 2024 Europea n
y Special
Biotechnolog
Preview Autumn 2024 © Boehringer Ingelheim
Publication date: 26 September, 2024
CDMOs & CROs
Hot topics in contract research to biomanufacturing
CDMOs, CROs and packaging service providers are under great pressure to adapt to new drug formats, formulations and automated preclinical test procedures, while at the same time facing a global shortage of qualified personnel. In addition to classic antibody and conjugate drugs and various RNA drugs and vaccines, cell and gene therapies that are increasingly complex to produce, the first in vivo CRISPR treatments or synthetic peptide hormone combinations – and, on the CRO side, cell- and organoid-based drug discovery technologies, new trial designs and AI – are entering the market. Become visible in EuropEan BiotEchnology ’ s CDMO & CRO special and present your offer/portfolio to customers.
Present your expertise
CDMOs & CROs, providers of modular production plants, equipment, AI, and experts in emerging areas will have the opportunity to present their latest products, services, and equipment in this special. EuropEan BiotEchnology goes out to decision makers throughout the entire European Life Science sectors. Take advantage of the journal’s highly relevant readership and grab this opportunity to target your audience!
Topics to be covered
CDMOs: Process development, automation, synbio, ATMPs, vector manufacturing, mRNA vaccines/therapeutics, ADCs, radio-conjugates, single use equipment, automated cell culture/sorting/seeding, media/cell line development, glyco-engineering, packaging, up- & downstream processing, fill & finish, QbD, combination therapies.
CROs: Stratification, drug discovery services, CRISPR, immunooncology, biomarker/drug approval, biosimilars, animal/organoid models, microfluidics, ADMET, adaptive trails, EMR-guided patient recruitment, remote monitoring, AI tools, iPSC-based models.
Editorial Deadline 11-09-2024
Editorial Contact:
Booking Deadline 13-09-2024
Marketing Contact:
Publication Date 26-09-2024
Marketing Contact: Thomas Gabrielczyk Oliver Schnell Andreas Macht
Tel.: +49-30-264921-50
Fax: +49-30-264921-11
Tel.: +49-30-264921-45
Fax: +49-30-264921-11
t.gabrielczyk@biocom.de o.schnell@biocom.de
Tel.: +49-30-264921-54
Fax: +49-30-264921-11
a.macht@biocom.de
BIOCOM Interrelations GmbH I Jacobsenweg 61 I 13509 Berlin I
www.biocom.de
Get on Board!
European Biotechnology Network
Europe: european-biotechnology.net
Austria: lifescienceaustria.at
United States: slas.org
Europe: medicinesforeurope.com
Germany: gasb.de
Ireland: ibec.ie/ibia
Portugal: www.p-bio.org
Italy: assobiotec.it
Spain: asebio.com
Switzerland: swissbiotech.org
Sweden: swedenbio.com
Young European Biotech Network
Europe: yebn.eu
Austria: biotechaustria.org
Norway: biotekforum.no
EuropE
Denmark: danskbiotek.dk The Netherlands: hollandbio.nl
UK: biopartner.co.uk
France: france-biotech.org
Hungary: hungarianbiotech.org
Europe: cebr.net
Finland: finbio.net Belgium: bio.be
european-biotechnology.com
Europe a n
following organisations:
Biotech nology is published in co-operation with the
Council E p B R io
an BiotEchnology covers the biotechnology sector of the current 27 EU member states, Norway, Switzerland, and UK. If you would like to subscribe, please refer to
& CROs Meet your audience!
Special:CDMOs